Incannex Healthcare Limited logo

Incannex Healthcare LimitedNASDAQ: IXHL

Profile

Sector:

Healthcare

Country:

Australia

IPO:

02 March 2022

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$36.52 M
-91%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector
-81%vs. 3y high
84%vs. sector
424.66
-90%vs. 3y high
98%vs. sector

Price

regular market | 49 min ago
$2.07+$0.07(+3.50%)

Dividend

No data over the past 3 years
$74.00 K-$5.42 M

Analysts recommendations

Institutional Ownership

IXHL Latest News

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
globenewswire.com24 October 2024 Sentiment: POSITIVE

NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato's drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, Novartis, and Solvay. He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
newsfilecorp.com02 October 2024 Sentiment: POSITIVE

Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Advancing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics Conducting FDA phase 2/3 trial, IHL-42X, for the treatment of Obstructive Sleep Apnea (OSA) IHL-42X pivotal phase 2 top-line data expected first half 2025 Click image above to view full announcement.

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
globenewswire.com05 August 2024 Sentiment: POSITIVE

NEW YORK and MELBOURNE, Australia, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies is pleased to announce that it has received approval from the US Food and Drug Administration (‘FDA') to conduct the Company's Investigational New Drug (‘IND') opening Phase 2 clinical trial. The trial will investigate Incannex's psilocybin pharmaceutical formulation, known as PSX-001, in conjunction with psychotherapy in patients with generalised anxiety disorder in the United States and the United Kingdom.

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
globenewswire.com30 May 2024 Sentiment: POSITIVE

NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company's Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep apnea (‘OSA').

What type of business is Incannex Healthcare Limited?

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

What sector is Incannex Healthcare Limited in?

Incannex Healthcare Limited is in the Healthcare sector

What industry is Incannex Healthcare Limited in?

Incannex Healthcare Limited is in the Drug Manufacturers - Specialty & Generic industry

What country is Incannex Healthcare Limited from?

Incannex Healthcare Limited is headquartered in Australia

When did Incannex Healthcare Limited go public?

Incannex Healthcare Limited initial public offering (IPO) was on 02 March 2022

What is Incannex Healthcare Limited website?

https://www.incannex.com

Is Incannex Healthcare Limited in the S&P 500?

No, Incannex Healthcare Limited is not included in the S&P 500 index

Is Incannex Healthcare Limited in the NASDAQ 100?

No, Incannex Healthcare Limited is not included in the NASDAQ 100 index

Is Incannex Healthcare Limited in the Dow Jones?

No, Incannex Healthcare Limited is not included in the Dow Jones index

When was Incannex Healthcare Limited the previous earnings report?

No data

When does Incannex Healthcare Limited earnings report?

The next expected earnings date for Incannex Healthcare Limited is 14 February 2025